Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Swedish researchers have identified genetic variants that increase the risk of atherosclerosis. The aim is for these new ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse ...

Individuals testing positive for human papillomavirus (HPV) had a 40% greater risk for overall cardiovascular disease (CVD) ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Large animal models are pivotal in the realm of preclinical cardiovascular research, offering critical insights that bridge ...